Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01905787
Recruitment Status : Recruiting
First Posted : July 23, 2013
Last Update Posted : August 9, 2017
Sponsor:
Information provided by (Responsible Party):
Dr Koren Ariel, HaEmek Medical Center, Israel

Brief Summary:
The purpose of this study is to take advance of the presence of two different cohorts of SCA patients in one country, the first group included SCA patients from Bedouin Arab origin that lives in Israel for more than one century and originally comes from African countries or Saudi Arabia, those patients lives in north east Israel and are treated at the Hematology Unit of the Emek Medical Center, the second group are SCA patients from African origin that come to Israel in the last decades and belong to original African population, this group receive treatment at the Pediatric Hematology Unit, Dana Children's Hospital, Ichilov Medical Center. A third group is a cohort of SCA patients treated at Schneider Children's Hospital Hematology Unit. Those patients belong also to the Israel Arab population and patients from a village that African Muslims live for many years. The characteristics of the three groups will be compared to the characteristics of a fourth group, a cohort of Afro-American SCA patients that are followed up and treated at the Pediatric Hematology Unit, Detroit Children's Medical Center, Detroit, Michigan, USA.

Condition or disease
Sickle Cell Anemia Sickle Cell β+ or β0 Thalassemia

Detailed Description:

Group 1 - Emek group - (EMC): 100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).

Group 2 - Dana group - (DMC): 50 patients will be included in the study. Group 3 - Schneider group - (ShMC): 50 patients will be included in the study. Group 4 - Detroit group - (WYUMC): 100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).

Patients with Sickle cell hemoglobin C (SC) and Sickle cell hemoglobin D (SD) disease will not be included as part of the study analysis due to the small numbers of patients expected, but the investigators are encouraged to report the data of those patients for further analysis.

Age: No age limits, patients can be included since diagnosis till age 40 since teenagers and young adults are often treated at pediatric hematology units.

Gender: Males and Females will be included in the study. Pregnant patients: Pregnancy will not be considered as exclusion criteria. Data about pregnancy under Hydroxyurea treatment both in females and in males should be included, including malformations in the offspring. It needs to be emphasized that the recommendation to the patients in both sexes is to stop Hydroxyurea treatment at last three months before conception.

Data collection: Data will be collected from the medical files. Demographic and family history and laboratory findings at diagnosis will be included.

Genetic mutations of the β globin gene in patients with Sickle Cell β thalassemia will be included if previously analyzed and recorded in medical files. Also α globin mutations and SCA haplotypes will be included if they were previously analyzed and are part of the data already present in the medical files.

Further genetic analysis including β and α globin mutations, haplotypes and xmn1 polymorphism will be included in an extension study but those analysis are not an integral part of this initial study unless they were performed before this present study.

Clinical complaints from the last 10 years will be summarized. Iron chelation and Hydroxyurea treatment given in the last 10 years will be summarized.

Complications that were diagnosed at any age will also be recorded.

Exclusion criteria:

  • Patients without sufficient data at the medical files due to lack of regular follow up will be excluded.
  • Patients that give explicit refuse in participation.

Inclusion criteria:

  • All the patients currently treated and followed up at the centers in Israel will be included.
  • A similar number of patients at same age range and same diagnosis will be included from the whole cohort at Detroit MC. Since at Detroit MC a significant larger number of patients, the criteria for patient's selection at this center will be a cohort matched for gender and age to the Israel patients.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study. Clinical and Genetic Characteristics of Sickle Cell Anemia (SCA) Patients in Three Different Communities.
Study Start Date : January 2012
Estimated Primary Completion Date : December 31, 2017
Estimated Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia

Group/Cohort
Group 2 - Dana group
50 patients will be included in the study.
Group 3 - Schneider group
50 patients will be included in the study
Group 4 - Detroit group
100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
Group 1 - Emek group
100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).



Primary Outcome Measures :
  1. Clinical comparative study between four different Sickle Cell Populations [ Time Frame: 5 years ]
    Clinical events during the observational period including crises, blood transfusions requirements and hospitalizations.


Secondary Outcome Measures :
  1. Clinical severity and laboratory results related to the Sickle Cell disease [ Time Frame: 5 years ]
    Laboratory analysis results (Blood count, Hgb F and tests related to hemolysis) will be compared between the different groups


Other Outcome Measures:
  1. Retrospective summary to the response to Hydroxyurea Therapy [ Time Frame: 5 years ]
    From all the groups patients treated by hydroxyurea will be compared between them and between treated patients to patients that did not receive hydroxyurea in terms of clinical events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Group 1 - Emek group - (EMC): 100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).

Group 2 - Dana group - (DMC): 50 patients will be included in the study. Group 3 - Schneider group - (ShMC): 50 patients will be included in the study. Group 4 - Detroit group - (WYUMC): 100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).

Criteria

Inclusion Criteria:

  • All patients followed up in the centers that participate in the study.
  • Pregnancy will not be considered as exclusion criteria.

Exclusion Criteria:

  • Patients with SC and SD disease will not be included.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01905787


Contacts
Layout table for location contacts
Contact: Ariel Koren, MD 97246495576 koren_a@clalit.org.il

Locations
Layout table for location information
United States, Michigan
Children's Hospital of Michigan, Detroit Medical Center - Wayne State University Not yet recruiting
Detroit, Michigan, United States
Contact: Sharada A Sarniak, MD         
Israel
Pediatric Hematology Unit HaEmek Medical Center Recruiting
Afula, Israel, 18101
Contact: Ariel Koren, MD    97246495576    koren_a@clalit.org.il   
Sub-Investigator: Carina Levin, MD         
Sub-Investigator: MIchael Ruimi, student         
Pediatric Hematology Unit - Schneider Children's Hospital - Beilinson Medical Center Not yet recruiting
Petah Tikva, Israel
Contact: Hanna Tamary, MD         
Sub-Investigator: Yohanna Yakubobich, MD         
Pediatric Hematology Unit - Dana Children's Hospital - Ichilov Medical Center Not yet recruiting
Tel Aviv, Israel
Contact: Ronit El Hasid         
Sub-Investigator: Dror Levin, MD         
Sponsors and Collaborators
HaEmek Medical Center, Israel

Layout table for additonal information
Responsible Party: Dr Koren Ariel, Head of Pediatric Dpt B, HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT01905787     History of Changes
Other Study ID Numbers: 0128-11-EMC
First Posted: July 23, 2013    Key Record Dates
Last Update Posted: August 9, 2017
Last Verified: August 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Thalassemia
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn